Literature DB >> 17304667

Tumor necrosis factor (TNF) can paradoxically increase on etanercept treatment, occasionally contributing to TNF-mediated disease.

Ajay Bhatia, Richard E Kast.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17304667

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


× No keyword cloud information.
  10 in total

1.  A mathematical analysis of rebound in a target-mediated drug disposition model: I.without feedback.

Authors:  Philip J Aston; Gianne Derks; Balaji M Agoram; Piet H van der Graaf
Journal:  J Math Biol       Date:  2013-04-17       Impact factor: 2.259

2.  Local versus systemic anti-tumour necrosis factor-α effects of adalimumab in rheumatoid arthritis: pharmacokinetic modelling analysis of interaction between a soluble target and a drug.

Authors:  David Stepensky
Journal:  Clin Pharmacokinet       Date:  2012-07-01       Impact factor: 6.447

3.  Insulin-like Growth Factor 1 and Adiponectin and Associations with Muscle Deficits, Disease Characteristics, and Treatments in Rheumatoid Arthritis.

Authors:  Joshua F Baker; Joan Marie Von Feldt; Sogol Mostoufi-Moab; Woojin Kim; Elena Taratuta; Mary B Leonard
Journal:  J Rheumatol       Date:  2015-09-01       Impact factor: 4.666

4.  [First manifestation of psoriasis vulgaris in tumor necrosis factor receptor-associated periodic syndrome during treatment with etanercept].

Authors:  S Boms; T Sehr; U Jappe; A Enk
Journal:  Hautarzt       Date:  2008-08       Impact factor: 0.751

5.  The impact of disease activity and tumour necrosis factor-α inhibitor therapy on cytokine levels in juvenile idiopathic arthritis.

Authors:  H M Walters; N Pan; T J A Lehman; A Adams; G D Kalliolias; Y S Zhu; F Santiago; J Nguyen; L Sitaras; S Cunningham-Rundles; T J Walsh; S S Toussi
Journal:  Clin Exp Immunol       Date:  2016-04-13       Impact factor: 4.330

6.  Relative expression and correlation of tumor necrosis factor-α, interferon-γ, and interleukin-17 in the rheumatoid synovium.

Authors:  Arata Nakajima; Yasuchika Aoki; Masato Sonobe; Fusako Watanabe; Hiroshi Takahashi; Masahiko Saito; Koichi Nakagawa
Journal:  Clin Rheumatol       Date:  2016-04-01       Impact factor: 2.980

7.  Ankylosing spondylitis and rheumatoid arthritis: serum levels of TNF-α and Its soluble receptors during the course of therapy with etanercept and infliximab.

Authors:  Martin Schulz; Helmut Dotzlaw; Gunther Neeck
Journal:  Biomed Res Int       Date:  2014-03-24       Impact factor: 3.411

8.  Combined Intraperitoneal and Intrathecal Etanercept Reduce Increased Brain Tumor Necrosis Factor-Alpha and Asymmetric Dimethylarginine Levels and Rescues Spatial Deficits in Young Rats after Bile Duct Ligation.

Authors:  Jiunn-Ming Sheen; Yu-Chieh Chen; Mei-Hsin Hsu; You-Lin Tain; Hong-Ren Yu; Li-Tung Huang
Journal:  Front Cell Neurosci       Date:  2016-06-23       Impact factor: 5.505

9.  Influence of Insulin Resistance and TNF-α on the Inflammatory Process, Oxidative Stress, and Disease Activity in Patients with Rheumatoid Arthritis.

Authors:  Neide Tomimura Costa; Tatiana Mayumi Veiga Iriyoda; Ana Paula Kallaur; Francieli Delongui; Daniela Frizon Alfieri; Marcell Alysson Batisti Lozovoy; Ricardo Braga Amin; Vinicius Daher Alvares Delfino; Isaias Dichi; Andréa Name Colado Simão
Journal:  Oxid Med Cell Longev       Date:  2016-05-31       Impact factor: 6.543

10.  Relationship between etanercept and thyroid function in patients with psoriasis vulgaris.

Authors:  Iulia Ioana Roman; Teodora Mocan; Meda-Sandra Orasan; Elena Mihaela Jianu; Carmen-Angela Sfrangeu; Remus-Ioan Orasan
Journal:  Clujul Med       Date:  2018-01-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.